Replies to post #105055 on Biotech Values

[Mpower]

No. Copaxone approval is not a limiting factor to "ink deals for other biologics." Sandoz/NVS seems to think MNTA is worth something....

"George says that partner Momenta Pharmaceuticals technical abilities in characterizing complex sugar molecules was key to getting the approval. Momenta’s technology “is highly differentiated and certainly played a significant role.”" (see http://blogs.forbes.com/sciencebiz/2010/07/26/novartis-honcho-golden-age-of-generic-biotech-drugs-is-coming/)